Pulmonary Embolism International THrOmbolysis Study-3

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 800 participants.

Also called NCT04430569

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 800 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04430569
  • EudraCT 2018-000816-96
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Romania, Serbia, Slovenia, Spain, Switzerland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04430569. Randomized; triple masking; primary purpose treatment. Start 2021-08-04 (actual); primary completion 2026-04-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pulmonary Embolism International THrOmbolysis Study-3
Acronym
PEITHO-3
Intervention (Drug)
Alteplase
Intervention (Drug)
Placebo
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Johannes Gutenberg University Mainz (class: other)
Collaborator
Life Sciences Research Partners (D Collen Research Foundation) (class: not stated)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
Instituto de Salud Carlos III (class: other government)
Collaborator
International Network of VENous Thromboembolism Clinical Research Networks (class: not stated)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04430569
Content hash
097634de6c81b6a74d1cade7f7add0b1eca0a22c3dd82dd604b4ec9ef72dad79